February 19, 2009 - The New England Journal of Medicine this week published the results from the SYNTAX trial, in ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
February 16 - The CYPHER SELECT Plus Sirolimus-eluting Coronary Stent has received CE marking within the European ...
Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in ...
February 9, 2009 - Implantation of drug-eluting stents to treat degenerative in aortocoronary saphenous vein graft ...
February 6, 2009 - Boston Scientific Corp. yesterday submitted to the FDA the final modules of the company’s pre ...
February 6, 2009 - Premier Purchasing Partners yesterday announced new agreements for drug-eluting coronary stents ...
February 3, 2009 – Medtronic has completed enrollment in PROTECT, the company’s global study comparing its ...
February 2, 2009 - Boston Scientific Corp. today said it began patient enrollment in the PLATINUM clinical trial ...
January 29, 2009 - Boston Scientific Corp. said today it received approval from the Japanese Ministry of Health ...
January 28, 2009 - Boston Scientific Corp. and Medtronic Inc. today announced the settlement of two lawsuits and an ...
January 28, 2009 - Data published this week in the online journal Circulation from the SPIRIT III U.S. pivotal ...
January 28, 2009 - SurModics Inc. and Nexeon MedSystems Inc. this week signed a licensing agreement to collaborate on ...
January 23, 2009 - Isotechnika Inc. said yesterday that partner Atrium Medical Corp. has completed patient enrollment ...
January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing ...
January 6, 2009 - Boston Scientific Corp. today said it acquired Labcoat Ltd., a privately held, development-stage drug ...